Siwa Biotech

A need for new monoclonal blood grouping reagents (BGRs) is evidenced by the age and declining performance of cell lines used in the manufacture of many BGRs currently on the market. Realizing this, Siwa scientists dedicated themselves to developing new monoclonal antibodies with improved performance characteristics. Siwas new IgM monoclonal antibo... dies are expressed from state-of-the-art recombinant Chinese Hamster Ovary (CHO) cell lines and have been incorporated into new BGRs for tube testing. Siwas recombinant IgM monoclonal Anti-Fya and recombinant IgM monoclonal Anti-Fyb BGRs are now FDA licensed. Recombinant BGRs with other specificities are in our development pipeline. Siwa Biotech is introducing new monoclonal IgM Anti-Fya and Anti-Fyb Blood Grouping Reagents (BGRs). Unlike ordinary monoclonal antibodies, Siwas Anti-Fya and Anti-Fyb are the first recombinant BGRs licensed by the FDA. Recombinant BGRs for Kell, Cellano, Jka, Jkb, S, s as well as other specificities are in our development pipeline. Recombinant monoclonal antibodies are already being widely used today in miracle cancer therapeutics. Siwa is the first company to apply this same technology to BGRs. Siwa scientists accomplished this by isolating antibody gene sequences and using genetic engineering technology to create antibodies with improved performance characteristics. This has allowed Siwa to develop unique one-step Duffy IgM BGRs that eliminate the need for AHG, incubations and washing steps, saving time for the technologist. To produce these antibodies, Siwa scientists introduced these improved antibody genes into Chinese Hamster Ovary (CHO) cells. These recombinant CHO cells then express our proprietary monoclonal antibodies which are incorporated into Siwas unique BGRs. These recombinant CHO cells should ensure a long term, consistent and stable supply of our antibodies. We believe this approach to the rare BGR space where the average hybridoma or heterohybridoma cell line is over twenty years old, will be very productive. Lea has ...Read More